An FDA program to fast-track drug reviews has become a way for the White House to influence which medicines make their way fastest to patients ...

BioMarin said it is acquiring Amicus Therapeutics, maker of rare-disease drugs, for $4.8 billion. A new FDA program meant to ...

BioMarin is acquiring Amicus Therapeutics for $4.8 billion, merging two rare disease-focused biotechs founded around the turn ...

The Trump administration has announced sweeping policies that, if enacted, could effectively end gender-affirming care for ...

Two government officials told STAT that the White House has been involved in final decisions about the FDA's new priority ...

The U.K. government wants to boost the local life sciences industry, and it hopes to entice American venture capital firms to ...

The New York Times once called John Lamattina, then Pfizer head of R&D, “Dr. Optimistic.” He’s not so optimistic now.

Every major pharmaceutical breakthrough in the past 40 years started with taxpayer-funded basic research: mRNA vaccines, ...

Republicans in Congress are making a renewed push before the end of the year to pass major federal restrictions to ...

The award is in response to an “unsolicited proposal,” according to documents in the Federal Register. The University of ...

OnPoint, the nation's first supervised drug consumption site, vows to continue its approach to harm reduction.

More than three dozen state AGs are urging Meta to better enforce its policies to thwart a “surge of misleading” ads for ...